The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 29, 2023
Filed:
Apr. 11, 2019
Applicant:
Clarity Pharmaceuticals Limited, Eveleigh, AU;
Inventors:
Matthew John Harris, Hunters Hill, AU;
Sean Lumb, Eveleigh, AU;
Assignee:
CLARITY PHARMACEUTICALS LIMITED, Eveleigh, AU;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 51/00 (2006.01); A61M 36/14 (2006.01); A61K 51/04 (2006.01); A61K 9/08 (2006.01); A61K 49/10 (2006.01); A61P 35/00 (2006.01); A61K 31/495 (2006.01); A61K 31/395 (2006.01);
U.S. Cl.
CPC ...
A61K 51/0482 (2013.01); A61K 9/08 (2013.01); A61K 49/106 (2013.01); A61K 31/395 (2013.01); A61K 31/495 (2013.01); A61K 51/044 (2013.01); A61K 51/0497 (2013.01); A61P 35/00 (2018.01);
Abstract
Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine ligands coordinated to a radioisotope, such as 64-copper, and linked to a tetrazine group for reaction with tumour targeting antibodies having functional reactive groups such as trans-cyclooctene, processes of preparing said radioligand formulations, and uses thereof for radioimaging, diagnosing and treating cancer.